Abstract

Purpose: To apply and evaluate Bayesian inter-product quantitative methods for signaling an excess of adverse events to specific pharmaceutical products, taking into account sales data as well as other information accessible to a company's drug-monitoring system. Methods: The Bayesian confidence propagation neural network (BCPNN) and the gamma Poisson shrinkage (GPS) were applied to a selected sample of spontaneously reported adverse events following the administration of a Bracco contrast medium. Both the conventional approach and sales data were exploited to represent the patients' population drug exposure. Results: Available data allow the detection of potential safety issues of a drug in comparison to those expected in its pharmaceutical category. No difference in signal detection performance between the BCPNN and GPS methods was found. Instead, adjustment by sales data markedly affected the signals detected, with the desirable property of preserving the risk order, for any given adverse drug reaction...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.